CD47 is a well‐known ‘don't eat me’ signal in DLBCL and the therapeutic utility of blocking antibody alone or a combination of blocking antibodies of CD47 ligand, SIRPα, or combination CD47 antibody and rituximab are in clinical trials [47, 48, 49]. Here, SIRPA is linked to diffuse large B-cell lymphoma.